Details of the Drug
General Information of Drug (ID: DMGBPSH)
Drug Name |
Homatropine Methylbromide
|
||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Arkitropin; Camatropine; Equipin; Esopin; Homapin; Homatromide; Malcotran; Mesopin; Methylhomatropine; Novatrin; Novatrine; Novatropine; Npvatropine; Sethyl; Homatropine methobromide; Homatropine methyl bromide; Homatropini methylbromidum; Humulon lead salt; Methyl Bromide Homatropine; Methylhomatropine bromide; Methylhomatropinum bromatum; Metilbromuro de homatropina; Omatropina metilbromuro; Omatropina metilbromuro [DCIT]; Tropinium methobromide mandelate; DL-Homatropine methyl bromide; DL-Methylbromide; Equipin (TN); Homapin-10; Homapin-5; Homatropine DL-methylbromide; Homatropine methylbromide (USP); Homatropine methylbromide [INN:BAN]; Homatropini methylbromidum [INN-Latin]; Hycodan, probilagol; Isopto Homatropine (TN); Methylbromure d'homatropine; Metilbromuro de homatropina [INN-Spanish]; N-Methylhomatropinium Bromide; Sed-Tems; Methylbromure d'homatropine [INN-French]; HOMATROPINIUM, 8-METHYL-, BROMIDE; [(5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate bromide; (8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl) 2-hydroxy-2-phenylacetate bromide; 3-[2-hydroxy(phenyl)acetoxy]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; 3-alpha-Hydroxy-8-methyl-1-alpha-H,5-alpha-H-tropanium bromide mandelate; 3-{[hydroxy(phenyl)acetyl]oxy}-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide; 3alpha-Hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide mandelate; 8-Methylhomatropinium bromide
|
||||||||||||||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||||||||||||||
Therapeutic Class |
Antiulcer Agents
|
||||||||||||||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||||||||||||||
Structure | |||||||||||||||||||||||||||||||||||
3D MOL is unavailable | 2D MOL | ||||||||||||||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 |
Molecular Weight | 370.3 | |||||||||||||||||||||||||||||||||
Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||||||||||||||||||
Rotatable Bond Count | 4 | ||||||||||||||||||||||||||||||||||
Hydrogen Bond Donor Count | 1 | ||||||||||||||||||||||||||||||||||
Hydrogen Bond Acceptor Count | 4 | ||||||||||||||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||||||||||||||
Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | ||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||